The 2026 MHE Pharmacy Survey asked questions about most-favored nation drug pricing, PBM reform and HHS Secretary Robert F. Kennedy Jr.'s vaccine policies. Respondents rated direct-to-consumer drug sales by drugmaker as the most important development in the pharmaceutical sector this year.
Lack of federal legislation and consolidation of hospitals into large health systems are among the reasons states are getting more involved in healthcare regulation and oversight.
The former chief health officer for Oracle sees artificial intelligence as the way to incorporate the many nonclinical factors that affect health into healthcare.
The pill version of Wegovy was available in January after the FDA approved it in December 2025. Eli Lillyʼs competitor, Foundayo (orforglipron) was approved by the FDA on April 1.
Lindsay Greenleaf, J.D., MBA, and Nicolas Ferreyros offered insight and analysis during a March 3 webinar about healthcare policy and politics.
Risant’s CEO, Jaewon Ryu, M.D., J.D., discusses some of the early successes of bringing a set of Kaiser Permanente’s value-based care practices to Risant's health systems—Geisinger Health in Pennsylvania and Cone Health in North Carolina. Consistency and "systemness” are key.
